No products

Shipping 0,00 €
Total 0,00 €

Cart Check out


Currently, many patients experiencing the Endotherapy multivalent and demonstrate the improvement in their condition, their hopes.

Any drug therapy must be approved by the various phases of clinical trials to receive Authorisation Market (AMM).

Thanks to the generosity of its donors, The IDRPHT was able to finance the early stages of clinical trials Endotherapy multivalent. The results show that the individualized treatments have no toxicity and do not cause any unwanted side effects.
At present, funding and conducting clinical trials on a larger scale are needed for the multivalent Endotherapy be recognized by public health authorities.

The IDRPHT called for the support of its donors to continue to fund research conducted by the team of Dr. Michel GEFFARD.


To pay the sum required, thank you to choose the amount below or multiples thereof for your donation.